# Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.

**Autores:** Chen P, Zhao T, Bi Z et al.
**Revista:** Future Oncol (2021)
**PMID:** 33878939 | **PMCID:** —
**DOI:** [10.2217/fon-2020-1231](https://doi.org/10.2217/fon-2020-1231)
**Fuente:** PubMed (abstract only — full text vía DOI)

## Relevancia
Análisis de respuesta axilar y conversión a ypN0 en cáncer de mama HER2+ tratado con quimioterapia neoadyuvante anti-HER2; relevante para definir candidatas a desescalada quirúrgica axilar.

## Abstract
The purpose was to integrate clinicopathological and laboratory indicators to predict axillary nodal pathologic complete response&#xa0;(apCR) after neoadjuvant therapy (NAT). The pretreatment clinicopathological and laboratory indicators of 416 clinical nodal-positive breast cancer patients who underwent surgery after NAT were analyzed from April 2015 to 2020. Predictive factors of apCR were examined by logistic analysis. A nomogram was built according to logistic analysis. Among the 416 patients, 37.3% achieved apCR. Multivariate analysis showed that age, pathological grading, molecular subtype and neutrophil-to-lymphocyte ratio were independent predictors of apCR. A nomogram was established based on these four factors. The area under the curve (AUC) was 0.758 in the training set. The validation set showed good discrimination, with AUC of 0.732. In subtype analysis, apCR was 23.8, 47.1 and 50.8% in hormone receptor-positive/HER2-, HER2+ and triple-negative subgroups, respectively. According to the results of the multivariate analysis, pathological grade and fibrinogen level were independent predictors of apCR after NAT in HER2+ patients. Except for traditional clinicopathological factors, laboratory indicators could also be identified as predictive factors of apCR after NAT. The nomogram integrating pretreatment indicators demonstrated its distinguishing capability, with a high AUC, and could help to guide individualized treatment options.

## Acceso
Vía [DOI](https://doi.org/10.2217/fon-2020-1231) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.2217/fon-2020-1231*
